Phenotypes Associated with This Genotype

Genotype
MGI:3763090

• Allelic Composition: Bglap/Bglap2^tm1Kry/Bglap/Bglap2^tm1Kry
• Genetic Background: involves: 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

decreased adipocyte glucose uptake ( J:126780 )

• white adipose glucose uptake, 7.5+/-0.9 nmol/g/min compared to 16.7+/-2.7 nmol/g/min in wild-type mice

oligozoospermia ( J:170888 )

♂ • worsening with time

abnormal spermatid morphology ( J:170888 )

♂ • decreased numbers

abnormal spermatocyte morphology ( J:170888 )

♂ • decreased numbers

decreased pancreatic beta cell proliferation ( J:126780 )

• beta-cell proliferation is decreased by two-fold compared to in wild-type mice

reproductive system

reproductive system phenotype ( J:170888 )

N • female mice exhibit normal female fertility, ovary weight, morphology of the uterus, follicles number, and circulating levels of sex steroid hormones

N • male germ cell proliferation is normal

oligozoospermia ( J:170888 )

♂ • worsening with time

abnormal spermatid morphology ( J:170888 )

♂ • decreased numbers

abnormal spermatocyte morphology ( J:170888 )

♂ • decreased numbers

decreased seminal vesicle weight ( J:170888 )

♂ • worsening with time

abnormal seminiferous tubule epithelium morphology ( J:170888 )

♂ • the size of the epithelium in testis tubules is decreased compared to in wild-type mice

decreased Leydig cell number ( J:170888 )

♂

small testis ( J:170888 )

♂ • at 3 months of age

decreased testis weight ( J:170888 )

♂ • at 3 months of age

decreased epididymis weight ( J:170888 )

♂ • worsening with time

homeostasis/metabolism

decreased circulating testosterone level ( J:170888 )

increased circulating estradiol level ( J:170888 )

increased circulating luteinizing hormone level ( J:170888 )

• 2.5-fold

increased circulating triglyceride level ( J:126780 )

decreased energy expenditure ( J:126780 )

abnormal glucose homeostasis ( J:126780 )

decreased insulin secretion ( J:126780 )

• mice exhibit decreased insulin secretion

• however, treatment of mice with recombinant osteocalcin increases insulin secretion

increased circulating glucose level ( J:126780 )

decreased circulating insulin level ( J:126780 )

impaired glucose tolerance ( J:126780 )

insulin resistance ( J:126780 )

adipose tissue

increased total body fat amount ( J:126780 )

abnormal fat cell morphology ( J:126780 )

• adipocyte number is increased (125.6+/-10.6x10³ adipocytes per fat pad compared to 93.2+/-10.7x10³ adipocytes per fat pad in wild-type mice)

decreased adipocyte glucose uptake ( J:126780 )

• white adipose glucose uptake, 7.5+/-0.9 nmol/g/min compared to 16.7+/-2.7 nmol/g/min in wild-type mice

endocrine/exocrine glands

decreased pancreatic beta cell proliferation ( J:126780 )

• beta-cell proliferation is decreased by two-fold compared to in wild-type mice

abnormal pancreatic islet morphology ( J:126780 )

• mice exhibit decreased islet size and number, beta-cell mass, and pancreas insulin content

decreased pancreatic beta cell mass ( J:126780 )

• mice exhibit decreased beta-cell mass

decreased pancreatic islet number ( J:126780 )

small pancreatic islets ( J:126780 )

decreased seminal vesicle weight ( J:170888 )

♂ • worsening with time

abnormal seminiferous tubule epithelium morphology ( J:170888 )

♂ • the size of the epithelium in testis tubules is decreased compared to in wild-type mice

decreased Leydig cell number ( J:170888 )

♂

small testis ( J:170888 )

♂ • at 3 months of age

decreased testis weight ( J:170888 )

♂ • at 3 months of age

decreased insulin secretion ( J:126780 )

• mice exhibit decreased insulin secretion

• however, treatment of mice with recombinant osteocalcin increases insulin secretion